TY - JOUR
T1 - Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia
AU - Relling, Mary V.
AU - Yang, Wenjian
AU - Das, Soma
AU - Cook, Edwin H.
AU - Rosner, Gary L.
AU - Neel, Michael
AU - Howard, Scott
AU - Ribeiro, Raul
AU - Sandlund, John T.
AU - Pui, Ching Hon
AU - Kaste, Sue C.
PY - 2004
Y1 - 2004
N2 - Purpose: One of the adverse effects of therapy for acute lymphoblastic leukemia (ALL) is osteonecrosis of the hip. Putative risk factors for osteonecrosis have included being female, white race, and older age. Our goal was to define possible genetic risk factors for osteonecrosis among children treated for newly diagnosed ALL. Methods: Using a candidate gene approach, we determined the genotypes for 16 common polymorphisms in genes likely to affect the pharmacokinetics or pharmacodynamics of antileukemic medications in 64 children with ALL. Therapy included glucocorticoids and antifolates. Magnetic resonance imaging of both hips was used to diagnose osteonecrosis, and was performed at similar times from the start of ALL therapy (P = .61 ) in the 25 patients with and the 39 patients without osteonecrosis (median, 447 days and 443 days, respectively). Results: In addition to age older than 10 years (odds ratio [OR], 24.2; P = .0001) and white race (OR, 11.1; P = .037), host factors for osteonecrosis included the vitamin D receptor Fokl start site CC genotype (OR, 4.5; P = .045), and the thymidylate synthase low activity 2/2 enhancer repeat genotype (OR, 7.4; P = .049). Conclusion: Because folate-related and vitamin D-receptor genetic variants have been associated with bone and vasculature morbidity, these pharmacogenetic associations likely reflect the interaction of antileukemic medications with germline sensitivity to drug actions, and might identify ALL patients at highest risk to develop osteonecrosis.
AB - Purpose: One of the adverse effects of therapy for acute lymphoblastic leukemia (ALL) is osteonecrosis of the hip. Putative risk factors for osteonecrosis have included being female, white race, and older age. Our goal was to define possible genetic risk factors for osteonecrosis among children treated for newly diagnosed ALL. Methods: Using a candidate gene approach, we determined the genotypes for 16 common polymorphisms in genes likely to affect the pharmacokinetics or pharmacodynamics of antileukemic medications in 64 children with ALL. Therapy included glucocorticoids and antifolates. Magnetic resonance imaging of both hips was used to diagnose osteonecrosis, and was performed at similar times from the start of ALL therapy (P = .61 ) in the 25 patients with and the 39 patients without osteonecrosis (median, 447 days and 443 days, respectively). Results: In addition to age older than 10 years (odds ratio [OR], 24.2; P = .0001) and white race (OR, 11.1; P = .037), host factors for osteonecrosis included the vitamin D receptor Fokl start site CC genotype (OR, 4.5; P = .045), and the thymidylate synthase low activity 2/2 enhancer repeat genotype (OR, 7.4; P = .049). Conclusion: Because folate-related and vitamin D-receptor genetic variants have been associated with bone and vasculature morbidity, these pharmacogenetic associations likely reflect the interaction of antileukemic medications with germline sensitivity to drug actions, and might identify ALL patients at highest risk to develop osteonecrosis.
UR - http://www.scopus.com/inward/record.url?scp=5444266905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=5444266905&partnerID=8YFLogxK
U2 - 10.1200/JCO.2004.11.020
DO - 10.1200/JCO.2004.11.020
M3 - Article
C2 - 15459215
AN - SCOPUS:5444266905
SN - 0732-183X
VL - 22
SP - 3930
EP - 3936
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 19
ER -